Effects of Orlistat, a Lipase Inhibitor, on the Pharmacokinetics of Three Highly Lipophilic Drugs (Amiodarone, Fluoxetine, and Simvastatin) in Healthy Volunteers

@article{Zhi2003EffectsOO,
  title={Effects of Orlistat, a Lipase Inhibitor, on the Pharmacokinetics of Three Highly Lipophilic Drugs (Amiodarone, Fluoxetine, and Simvastatin) in Healthy Volunteers},
  author={Jianguo Zhi and Rema Moore and Linda Kanitra and Thomas E. Mulligan},
  journal={The Journal of Clinical Pharmacology},
  year={2003},
  volume={43}
}
To investigate the effect of orlistat on the pharmacokinetics of three highly lipophilic drugs (amiodarone, fluoxetine, and simvastatin), the authors performed double‐blind, placebo‐controlled, randomized two‐period crossover (for fluoxetine and simvastatin) or parallel (for amiodarone) studies in healthy volunteers ages 18 to 65 years of a body mass index between 18 and 30 kg/m2. During treatment with orlistat or matching placebo for 5 to 13 ⅓ days, a single oral dose of highly lipophilic drug… 
Modeling the Relationship Between Drug Lipophilicity and Potential for an Interaction With Orlistat
  • J. Zhi
  • Medicine
    Journal of clinical pharmacology
  • 2012
TLDR
This logP model was further developed to relate the lipophilicity of the compounds over a wide range of their n-octanol/water partition coefficient, logP, to the potential for a drug–drug interaction to predict the likelihood of such an effect by the concomitant administration of orlistat.
Drug treatments for obesity: orlistat, sibutramine, and rimonabant
TLDR
As new drugs are developed, it is suggested that the assessment processes should include both surrogate endpoints and clinical outcomes, so that patients and their physicians can be confident that the putative benefits of such drugs outweigh their risks and costs.
Orlistat-Associated Adverse Effects and Drug Interactions
TLDR
The use of orlistat has been associated with several mild-to-moderate gastrointestinal adverse effects, such as oily stools, diarrhoea, abdominal pain and faecal spotting, and the clinical relevance and pathogenesis of these effects is discussed.
Herb-Drug Interaction of Paullinia cupana (Guarana) Seed Extract on the Pharmacokinetics of Amiodarone in Rats
TLDR
An herb-drug interaction between Paullinia cupana extract and amiodarone is reported for the first time, which determined a great decrease on amioarone bioavailability in rats.
Investigating herb-drug interactions: the effect of Citrus aurantium fruit extract on the pharmacokinetics of amiodarone in rats.
  • M. Rodrigues, G. Alves, A. Falcão
  • Medicine
    Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
  • 2013
TLDR
It deserves to be highlighted the significant increase of the peak plasma concentration of amiodarone in rats pre-treated with C. aurantium extract, while the extent of systemic exposure was comparable between both groups.
Herb-drug interaction of Fucus vesiculosus extract and amiodarone in rats: a potential risk for reduced bioavailability of amiodarone in clinical practice.
TLDR
The therapeutic efficacy of amiodarone may be compromised by the concurrent administration of herbal slimming medicines/dietary supplements containing F. vesiculosus, and this paper reports, for the first time, the herb-drug interaction between F. VesicULosus extract and amioarone.
Efficacy, safety and tolerability of orlistat, a lipase inhibitor, in the treatment of adolescent weight excess
TLDR
The goal of this article is to review the efficacy and safety of orlistat in adolescents, with emphasis on its effects on weight and body mass index, body composition and liposoluble vitamins during growth.
Effect of permeation enhancers on transdermal delivery of fluoxetine: in vitro and in vivo evaluation.
TLDR
The permeation parameters of FX through human cadaver skin were well correlated with that through hairless mouse and rat skin, suggesting that these animal models can be used for predicting the permeability ofFX through human skin.
The use of orlistat in the treatment of obesity, dyslipidaemia and Type 2 diabetes
TLDR
The incremental amount of weight loss that orlistat produces is modest, but sufficient to result in improvement in obesity comorbidities such as elevated blood pressure, dyslipidaemia and hyperglycaemia compared with diet and exercise alone.
Pharmacotherapy for obesity
TLDR
The goal of this article is to review currently available anti-obesity drugs so that physicians may apply the principle of pharmacologic treatment for obesity to obese patients in the real clinical situation.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 19 REFERENCES
Effect of the lipase inhibitor orlistat on the pharmacokinetics of four different antihypertensive drugs in healthy volunteers
TLDR
The lipase inhibitor orlistat given 50 mg 3 times daily does not alter the pharmacokinetics of atenolol, furosemide, nifedipine and captopril to a clinically significant extent.
Pharmacokinetic Evaluation of the Possible Interaction between Selected Concomitant Medications and Orlistat at Steady State in Healthy Subjects
TLDR
There was no effect of orlistat on the pharmacokinetics of selective concomitant medications when these drugs were taken concomitantly with orlistats, and equivalence was demonstrated for the two primary parameters for all drugs studied.
Lack of Pharmacokinetic Drug-Drug Interaction between Orlistat and Cerivastatin
TLDR
The objectives of the present study were to determine the influence of concurrent orlistat steady-state administration on the bioavailability and pharmacokinetics of cerivastatin and to speculate on the increase in pravastatin bioavailability due to an increase in its extent of absorption.
Lack of Effect of Orlistat on the Bioavailability of a Single Dose of Nifedipine Extended‐Release Tablets (Procardia XL) in Healthy Volunteers
TLDR
The 90% confidence intervals for the ratio of geometric least‐square means for maximum concentration (Cmax) and area under the concentration‐time curve (AUCo‐t) indicate that the bioavailability of nifedipine was not altered by treatment with orlistat.
Effect of Orlistat, a Novel Anti-Obesity Agent, on the Pharmacokinetics and Pharmacodynamics of Pravastatin in Patients with Mild Hypercholesterolaemia
TLDR
It is indicated that orlistat had no significant impact on the pharmacokinetics of pravastatin, and the percentage decreases from baseline in low density lipoprotein (LDL)-cholesterol and total cholesterol were similar after 6 days’ treatment.
The Influence of Orlistat on the Pharmacokinetics and Pharmacodynamics of Glyburide in Healthy Volunteers
TLDR
Orlistat administered at doses of 80‐mg three times daily does not significantly alter the pharmacokinetics and blood glucose‐lowering effect of a single 5‐mg oral dose of glyburide in healthy volunteers.
The Effect of Orlistat on the Pharmacokinetics of Phenytoin in Healthy Volunteers
TLDR
An approximately 30% reduction in dietary fat absorption induced by orlistat administered at doses of 120 mg three times daily did not significantly alter the pharmacokinetics of a single 300‐mg oral dose of phenytoin in healthy volunteers.
The Effect of Orlistat on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Volunteers
TLDR
Orlistat administered at doses of 120 mg three times daily did not significantly alter the pharmacokinetics and pharmacodynamics of a single 30‐mg oral dose of warfarin in healthy volunteers.
The interaction of the lipase inhibitor orlistat with ethanol in healthy volunteers
TLDR
Concomitant ingestion of social amounts of ethanol did not alter the inhibitory effect of orlistat on dietary fat absorption during short-term treatment (6 days) with or listat, and no significant difference was found regarding ethanol pharmacokinetic parameters between treatments with orlistsat and placebo.
The Influence of Reduced Dietary Fat Absorption Induced by Orlistat on the Pharmacokinetics of Digoxin in Healthy Volunteers
TLDR
The result suggests that a ∼30% reduction in dietary fat absorption will not change the efficacy of digoxin in cardiac patients, and the pharmacokinetics ofdigoxin was not altered by treatment with orlistat.
...
1
2
...